You searched for "Injection"
Anti-VEGF and PD-1 combinations in renal cell carcinoma
Over the past decade, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs) have been central to treating renal cell carcinoma (RCC), with oncologists refining dosing strategies to balance treatment efficacy with quality of life (QoL). Recently, the introduction of...June Medical’s Angela Spång wins top award at Goldman Sachs 10KSB
After a rigorous application and interview process, Angela Spång, Founder & Owner of award-winning medical device company, June Medical, secured a place on the Goldman Sachs 10KSB transformative programme. She embarked on what is considered to be a condensed mini...Use of MRI in the evaluation of prostate cancer: part 1
Introduction Prostate cancer remains the most commonly diagnosed cancer in males and the second leading cause of cancer related deaths in UK men, after lung cancer [1]. The incidence of prostate cancer in the UK has shown a rapid increase...The effect of COVID-19 on urology training
COVID-19 has affected all aspects of medicine. Urologists have been called upon to work in vastly different working environments including acute pan-surgical teams, intensive care and medical wards. The strategies put in place by hospital management teams vary significantly across...MRI screening for prostate cancer: a step towards a ‘prostagram’
The UK National Screening Committee has been calling for further research into alternative screening tests for prostate cancer. The committee decided against prostate cancer screening using prostate specific antigen (PSA) testing on the basis that “PSA is still a poor...
Curing pure CIS with radical surgery: lessons learned
As carcinoma in situ (CIS) theoretically has no ability to invade or metastasise, performing radical cystectomy for CIS-only disease should be curative. In this single centre review over 37 years, 1964 patients undergoing cystectomy were analysed with 52 undergoing surgery...
Intravesical cytosine arabinoside + Mitomycin C for bladder cancer – is it beneficial?
Mitomycin C (MMC) is often used as an intravesical therapy for low / intermediate risk non-muscle invasive bladder cancer. This randomised controlled trial (RCT) was designed to assess the safety and efficacy of MMC + cytosine arabinoside (Ara-C). Ara-C was...
Outcomes of sarcomatoid differentiation in urothelial carcinoma
Sarcomatoid differentiation is a rare variant of urothelial carcinoma (UC) seen in 0.6% of cases. Its response to neo-adjuvant chemotherapy (NAC) has not been well reported. The authors have done a retrospective analysis of patients undergoing cystectomy between 1995 and...
Preoperative risk stratification of high-risk prostate cancer patients
High-risk prostate cancer (HRPCa) is associated with a significant risk of recurrence after radical treatment. While several classification systems exist, the D’Amico criteria – based on clinical T stage ≥T2c, prostate specific antigen (PSA) ≥20 ng/mL, or Gleason score (GS)...Nonacus Clinical Services announce partnership with The London Clinic to deliver GALEAS™ Bladder test
Nonacus Clinical Services, the UK laboratory delivering genomic cancer testing services to the NHS and private healthcare providers, recently announced it is working with The London Clinic to help more patients benefit from its non-invasive GALEAS™ Bladder test for cancer....COVID-19: the impact on a junior registrar
Prior to the coronavirus pandemic I was a trust grade junior registrar, using this year at a district general hospital to gain experience, skills and portfolio points for round two of National Selection. My urology registrar on-call duties would consist...
